A 27-year-old patient with a history of severe obstetrical complications and arterial thrombosis received a diagnosis of hereditary thrombotic thrombocytopenic purpura (TTP) due to severe ADAMTS13 ...

Pyrrolizidine alkaloids (PAs), widely distributed in plants, are known to induce liver failure. Hepatic platelet accumulation has been reported during the progression of PA-induced liver injury ...

Takeda said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 for the ...

− cTTP is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90%1,2 − Approval Based on Totality of Evidence ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...

A key opinion leader explains how acquired TTP is diagnosed, with a focus on the use of ADAMTS13 testing. X. Long Zheng, MD, PhD: How do you actually diagnose TTP [thrombotic thrombocytopenic purpura] ...

Patients With ADAMTS13 Deficiency and/or TTP Experience High Clinical Burden An investigation into the burden of dilated perivascular spaces (dPVS) in children with sickle cell disease (SCD) confirmed ...

cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms Takeda Continues 70-plus Year Legacy of Driving Innovation for the Rare ...

In a recent article published in the journal Scientific Reports, researchers performed a prospective observational study in three healthcare centers in Germany to understand the impact of ADAMTS13 ...

Takeda announced it is launching Adzynma (ADAMTS13, recombinant-krhn) following the recent approval by the Food and Drug Administration. The drug is intended for the prophylactic and on-demand ...